Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic renal failure with an estimated glomerular filtration rate \< 60 milliliters per minute per 1.73 m\^2 and not expected to begin dialysis for at least 12 weeks.~2. Two consecutive hemoglobin values ≥ 8.0 g/dL and \< 11.0 g/dL within 4 weeks prior to randomization.~Exclusion Criteria:~1. Females who are pregnant or breast-feeding.~2. Treatment with an ESA in the 12 weeks prior to randomization.~3. Known intolerance to any ESA, parenteral iron supplementation, or pegylated molecule.~4. Prior chronic hemodialysis or chronic peritoneal dialysis treatment.~5. Known bleeding or coagulation disorder.~6. Known hematologic disease or cause of anemia other than renal disease.~7. Poorly controlled hypertension.~8. Evidence of active malignancy within one year prior to randomization~9. A scheduled kidney transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginesatide 0.025 mg/kg (Type: EXPERIMENTAL): None
- Peginesatide 0.04 mg/kg (Type: EXPERIMENTAL): None
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).